Follow the 이엔셀 stock price and the full management transaction log of the company, a publicly traded company based in South Korea. Shares are listed on the KR market, under the authority of DART (FSS). Operating in the Health Care sector, 이엔셀 has recorded 35 insider filings. Market capitalisation: €65.1bn. The latest transaction was filed on 25 June 2026 (Purchase). Among the most active insiders: 장종욱. Every trade is openly available.
33
Insider Decl.
n/a
Thresholds
n/a
27 ops.
Buy Volume
€1m
5 ops.
Sell Volume
20Σ signal
Buys n/a€1m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 28,825 of 29,062 companies
6.7
score / 100
Value
9
Quality
4
FCF yld-21%
Earn yld-25%
EV/EBITDA·
ROE-42%
Gross mgn-46%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
이엔셀 es una empresa farmacéutica y de atención médica que cotiza en el mercado XKRX. Se especializa en el desarrollo de soluciones innovadoras para el cuidado de la salud.